Drug-resistant pulmonary tuberculosis in Berlin, Germany, 1987-1993

Resistance of Mycobacterium tuberculosis (M.tb) strains is an increasing problem worldwide. Since no public health data are available for urban populations in Germany, we investigated resistance in our hospitalized patients (n = 1,011) over the last 7 yrs. We therefore evaluated clinical data and results of susceptibility tests (breakpoint technique/proportion method) for isoniazid, streptomycin, rifampin, pyrazinamide, protionamide and ethambutol. Since 1987, there has been a relatively constant rate of 5.9% (3.9%-7.8%) for single-drug resistance (SDR), but an increasing rate of multidrug-resistant (MDR) strains (> or = 2 first-line drugs) from 1.7% in 1987 to 5.8% in 1993. Sixty nine percent of patients with MDR strains showed resistance to two drugs, and 31% to three or more drugs. Risk factors for SDR and MDR tuberculosis revealed previous therapy (odds ratio (OR) (95% confidence interval (95% CI)); SDR 2.2 (1.7-4.0); MDR 4.5 (2.3-8.8)); and foreign-born status (SDR 2.2 (1.3-3.6); MDR 3.5 (1.8-6.8)) to be the most important factors associated with resistance. Both primary and acquired resistance were higher in foreign-born than in German-born patients. We conclude that there was a considerable increase in multidrug-resistant tuberculosis in our hospital from 1987 to 1993. Since previously treated patients and patients born in countries with a high level of primary resistance had an increased risk of drug-resistant tuberculosis, we would advise a four drug regimen as initial therapy in those patients.

This article has been cited by other articles:

				R. Erbes, K. Oettel, M. Raffenberg, H. Mauch, M. Schmidt-Ioanas, and H. Lode Characteristics and outcome of patients with active pulmonary tuberculosis requiring intensive care Eur. Respir. J., June 1, 2006; 27(6): 1223 - 1228. [Abstract] [Full Text] [PDF]

				R. Loddenkemper, D. Sagebiel, and A. Brendel Strategies against multidrug-resistant tuberculosis Eur. Respir. J., July 1, 2002; 20(36_suppl): 66S - 77s. [Abstract] [Full Text] [PDF]

				A. Lubasch, R. Erbes, H. Mauch, and H. Lode Sparfloxacin in the treatment of drug resistant tuberculosis or intolerance of first line therapy Eur. Respir. J., April 1, 2001; 17(4): 641 - 646. [Abstract] [Full Text] [PDF]